Cargando…

Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype

Resetting tumor-associated macrophages (TAMs) is a promising strategy to ameliorate the immunosuppressive tumor microenvironment and improve innate and adaptive antitumor immunity. Here we show that chloroquine (CQ), a proven anti-malarial drug, can function as an antitumor immune modulator that swi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Degao, Xie, Jing, Fiskesund, Roland, Dong, Wenqian, Liang, Xiaoyu, Lv, Jiadi, Jin, Xun, Liu, Jinyan, Mo, Siqi, Zhang, Tianzhen, Cheng, Feiran, Zhou, Yabo, Zhang, Huafeng, Tang, Ke, Ma, Jingwei, Liu, Yuying, Huang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830447/
https://www.ncbi.nlm.nih.gov/pubmed/29491374
http://dx.doi.org/10.1038/s41467-018-03225-9
Descripción
Sumario:Resetting tumor-associated macrophages (TAMs) is a promising strategy to ameliorate the immunosuppressive tumor microenvironment and improve innate and adaptive antitumor immunity. Here we show that chloroquine (CQ), a proven anti-malarial drug, can function as an antitumor immune modulator that switches TAMs from M2 to tumor-killing M1 phenotype. Mechanistically, CQ increases macrophage lysosomal pH, causing Ca(2+) release via the lysosomal Ca(2+) channel mucolipin-1 (Mcoln1), which induces the activation of p38 and NF-κB, thus polarizing TAMs to M1 phenotype. In parallel, the released Ca(2+) activates transcription factor EB (TFEB), which reprograms the metabolism of TAMs from oxidative phosphorylation to glycolysis. As a result, CQ-reset macrophages ameliorate tumor immune microenvironment by decreasing immunosuppressive infiltration of myeloid-derived suppressor cells and Treg cells, thus enhancing antitumor T-cell immunity. These data illuminate a previously unrecognized antitumor mechanism of CQ, suggesting a potential new macrophage-based tumor immunotherapeutic modality.